- Recent Funding
- Investors
- Novo Holdings
Novo Holdings portfolio
Novo Holdings has 22 portfolio companies on record at Recent Funding, with 6 investments in the last 12 months.
About this page
It is a family office based in Hellerup, DK, founded in 1999. It led 13 of the 28 rounds it joined. Its most recent investment on record is Commit Biologics's $60M Seed round in November 2026, alongside AbbVie, Ackermans & van Haaren, Ackermans & and 3 others. By category, its portfolio leans toward Health and bio (20) and Manufacturing and industrial (2). It has co-invested with Sound Bioventures, Sofinnova Partners and Catalio, most often Sound Bioventures (4 rounds).
About Novo Holdings
What Novo Holdings invests in
- Health and bio · 20 · 91%
- Manufacturing and industrial · 2 · 9%
- Data and analytics · 2 · 9%
- Education · 1 · 5%
- Commerce and retail · 1 · 5%
- Real estate and construction · 1 · 5%
Novo Holdings recent investments
| Company | Round | Date | Alongside |
|---|---|---|---|
| Seed · $60M | AbbVie, Ackermans & van Haaren (lead), Ackermans & (lead) +3 | ||
| Series B+ · $310M · lead | Jefferson Life Sciences, Janus Henderson Investors, Syncona Partners LLP +6 | ||
| Series B+ · $70.97M · lead | LLD Nybohov Invest AB, Industrifonden, The Ljungstrom Family Office (lead) +5 | ||
| Series A · $76.65M · lead | Catalyze Capital, The Ljungstrom Family Office, Pappas Capital +5 | ||
| Series B+ · $118M | Adage Capital Management, Janus Henderson Investors, Mass General Brigham Ventures +5 | ||
| Series B+ · $34.9M | Athos Capital, Cross-Border Impact Ventures (lead), Export and Investment Fund (lead) | ||
| Series A · $109.99M | Gilde Healthcare, Forbion Capital Partners, Catalio +1 | ||
| Series B+ · $130M · lead | Qatar Investment Authority, Agent Capital, Bristol-Myers Squibb +6 |
How Novo Holdings invests
Novo Holdings portfolio companies
CCommit Biologics$60MSeed · Nov 2026
OOMass Therapeutics$310MSeries B+ · Oct 2026
AAnaCardio$70.97MSeries B+ · Sep 2026
BBreye Therapeutics$76.65MSeries A · Sep 2026
CClaris Bio$118MSeries B+ · Jul 2026
BBactolife$34.9MSeries B+ · Jan 2026
SSidera Bio$109.99MSeries A · Nov 2025
GGlycoEra$130MSeries B+ · May 2025
GGlycomine$115MSeries B+ · May 2025
AAugustine Therapeutics$85MSeries A · Mar 2025
WWindward Bio$200MSeries A · Jan 2025
OOrbis Medicines$93MSeries A · Jan 2025
KKivu Bioscience$92MSeries A · Oct 2024
AAvenCell$112MSeries B+ · Oct 2024
MMyricx Bio$120MSeries A · Jul 2024
NNMD Pharma$80MSeries B+ · Nov 2023
IInspirna$50MSeries B+ · Jul 2022
RRondo Therapeutics$67MSeries A · Mar 2022
VVerana Health$150MSeries B+ · Jan 2022
AAgnext Taranjeet Bhamrabacker
TTribune Therapeutics ABbacker
PPhasecraftbacker
| Company | Round with Novo Holdings | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Seed · $60M | $77.19M | Nov 17, 2026 Seed |
Health and bio |
Series B+ · $310M · lead | $422.51M | Oct 15, 2026 Series B+ |
Health and bio |
Series B+ · $70.97M · lead | $89.97M | Sep 30, 2026 Series B+ |
Health and bio |
Series A · $76.65M · lead | $80.77M | Sep 29, 2026 Series A |
Health and bio |
Series B+ · $118M | $175M | Jul 28, 2026 Series B+ |
Health and bio |
Series B+ · $34.9M | $76.16M | Jan 6, 2026 Series B+ |
Health and bio |
Series A · $109.99M | $109.99M | Nov 4, 2025 Series A |
Health and bio |
Series B+ · $130M · lead | $179M | May 27, 2025 Series B+ |
Health and bio |
Series B+ · $115M | $195M | May 9, 2025 Series B+ |
Health and bio |
Series A · $85M · lead | $103.17M | Mar 24, 2025 Series A |
Health and bio |
Series A · $200M · lead | $200M | May 5, 2026 round |
Health and bio |
Series A · $93M | $121M | Jan 6, 2025 Series A |
Health and bio |
Series A · $92M · lead | $92M | Oct 28, 2024 Series A |
Health and bio |
Series B+ · $112M · lead | $112M | Oct 22, 2024 Series B+ |
Health and bio |
Series A · $120M · lead | $120M | Jul 8, 2024 Series A |
Health and bio |
Series B+ · $80M | $80M | Nov 15, 2023 Series B+ |
Health and bio |
Series B+ · $50M | $50M | Jul 11, 2022 Series B+ |
Health and bio |
Series A · $67M | $67M | Mar 2, 2022 Series A |
Health and bio |
Series B+ · $150M · lead | $202M | Apr 30, 2026 Series B+ |
Data and analytics |
backer | undisclosed | — |
Health and bio |
backer | undisclosed | Mar 27, 2025 Series A |
Real estate and construction |
backer | $34M | Oct 2, 2025 Series B+ |
Most frequent co-investors
SSound Bioventures4 shared rounds · last Sep 30, 2026
SSofinnova Partners4 shared rounds · last Jul 28, 2026
CCatalio4 shared rounds · last Jul 28, 2026
BBioqube Ventures3 shared rounds · last Nov 17, 2026
SSanofi Ventures3 shared rounds · last Oct 15, 2026
JJanus Henderson Investors3 shared rounds · last Oct 15, 2026
EExport and Investment Fund3 shared rounds · last Sep 29, 2026
FForbion Capital Partners3 shared rounds · last Nov 4, 2025
RRoche Venture Fund3 shared rounds · last May 27, 2025
AAbingworth3 shared rounds · last May 9, 2025
EEli Lilly3 shared rounds · last Mar 24, 2025
MM Ventures2 shared rounds · last Nov 17, 2026
Similar investors
MMirae Asset Capital22 companies · 9 deals in 12 mo
EEverywhere Ventures22 companies · 3 deals in 12 mo
OObvious Ventures22 companies · 3 deals in 12 mo
EEmerson Collective23 companies · 6 deals in 12 mo
EEarlybird VC23 companies · 2 deals in 12 mo
SSands Capital Ventures21 companies · 8 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.
Share is of the 28 rounds on Recent Funding that name Novo Holdings. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists Novo Holdings, which is a subset of its real portfolio. API: /api/v1/investors/novo-holdings (get a free API key). More: the most active VC firms and new venture capital funds.
The week's top funded startups and market insights, in your inbox every Monday.
Unsubscribe anytime · privacy